Crizotinib, an adenosine-triphosphate (ATP)-competitive smallmolecule inhibitor, was the first oral ALK inhibitor approved by the Food and Drug Administration (FDA) inAugust 2011 for the treatment of NSCLC to inhibit the receptor tyrosine kinasesALK, ROS1, and mesenchymal-epithelial transition (MET) [5, 6, 7, 8, 9]. Here, MET is linked to non-small cell lung carcinoma.